and Wanner, 2000) . Briefly, MG1655 was transformed with pKD46, which encodes lambda Red recombinase. Then the mCherry and kan genes were amplified by PCR from pBADANEImCherry&Kan, which codes for the pstI-mCherry fusion followed by the kan gene, using primers that contain homology to the 3' terminus of pstI and the 5' terminus of crr (located downstream of pstI on the E. coli chromosome). The resulting fragment was introduced into the pKD46-containing MG1655 strain by electroporation, and kanamycin-resistant colonies were isolated. Colonies not containing PKD46 were isolated after growth at an elevated temperature (Datsenko and Wanner, 2000) . MG1655, MG1655 pts, MG1655 (ptsI-mCherry), MA110 bgl [bgl-pho] & MA10 (bgl + ) (Mahadevan et al., 1987) , MA10 bgl + pts (Raveh et al., 2009) , and MA152, a bgl -strain that carries a bgl'-lacZ fusion on its chromosome (Mahadevan et al., 1987) , were used to test expression and functionality of the fusion proteins. LB medium, M9 salts, and M63 salts minimal media were prepared essentially as described by Miller (Miller) . MacConkey plates supplemented with different carbon sources were prepared from MacConkey agar (Difco).
Plasmids
Plasmids used for the fluorescence microscopy: pBADLL-mCherry was constructed as follows: a 288 amino acid fragment, which contains the RBS and the mCherry gene, was amplified by PCR from the plasmid pRSET-B (obtained from Roger Y. Tsien) with primers that introduced the SacI and XbaI sites. The fragment was ligated to pBAD18 (Guzman et al., 1995) , which was cleaved by SacI and XbaI. pBADLLHPr-mCherry and pBADLLEI-mCherry were constructed by amplifying the pstH and pstI genes from pLF-HPr and pLF-EI (Fux et al., 2003a) , respectively, with primers that introduced the NheI and SacI sites, and by ligating the amplified fragments to pBADLLmCherry, which was cleaved by NheI and SacI. pBADANSHPr-GFP was constructed by replacing the SacI-HindIII fragment encoding mCherry in pBADLLHPr-mCherry with the a fragment encoding GFP, which was amplified from pJS185 (Lopian et al., 2003) ) with oligonucleotides that introduced SacI and HindIII cleavage sites at the termini and the three analines linker. pBADLLHPrmCherry&EI and pBADLLEI-mCherry&HPr were constructed by amplifying the pstI and pstH genes from pLF-EI and pLF-HPr, respectively, with primers that introduced the SalI and HindIII by ligating the amplified fragments to pBADLLHPr-mCherry, which was cleaved by SalI and HindIII. pBADANEI-mCherry&Kan was constructed by amplifying the kan gene from pKD4 (Datsenko and Wanner, 2000) with primers that introduced the SalI and HinDIII sites, and ligating the amplified fragment to pBADLLEI-mCherry, which was cleaved by SalI and HinDIII. pLLK12F, which expresses the bglF gene, was constructed by ligating a 1878 bp XbaI-SalI PCR fragment encoding the bglF gene from pMN5, to the 5930 bp XbaI-SalI fragment of pJPK12 (Peterson and Phillips, 2008) . pLLK12F-GFP, which expresses BglF-GFP, was constructed by ligating a 720 bp HindIII-XhoI PCR fragment encoding the gfp gene from pJS185 to pLLK12F, which was cleaved with HindIII and XhoI. Cloning of the bglF gene in the pZ vector system was carried out in two steps. First, the first 515 bp of bglF were amplified by PCR and introduced between the Acc651 and Lutz and Bujard (Lutz and Bujard, 1997) , yielding pLL4. To construct pZLF, which expresses BglF under the control of the P LtetO-1 promoter, a 1656 bp HpaI-BamHI fragment from pT7OAC-F was ligated to the 4511 bp HpaI-BamHI fragment of pLL4. All fusion proteins constructed during this study for the fluorescence microscopy experiments contained a linker of three alanines between the studied protein and the fluorescent tag. glu -GFP in pJPA12 (that confers resistance to ampicillin). pJS185, which expresses a BglG-GFP fusion, was described before (Lopian et al., 2003) . pLLG(H160Y)-EGFP and pLLG(H208R)-EGFP were constructed by introducing the indicated mutations into pJS185 using a site-directed mutagenesis kit (Strategene). The mutations abolished the NsiI site and introduced a MluI site, respectively.
Plasmids used for the pull-down and the Far-Western assays: pLFHG was constructed by amplifying 842 bp fragment encoding BglG, by PCR from pOAC101 (Amster-Choder and Wright, 1992) , and cloning it between the NdeI-BamHI sites in pET15b (Novagen). pANSMG, pANSMG(D100N), pANSMG(H160Y), and pANSMG(H208R), which encode MBP-BglG, MBPBglG(D100N), MBP-BglG(H160Y), MBP-BglG(H208R), respectively, were described before (Lopian et al., 2003) . pMAL-c2, which codes for an MBP-LacZ' protein was purchased from NEB.
pANSM-PRD1 (Fux et al., 2003b) and pANSM-PRD2 (Fux et al., 2003b) were constructed by cloning the sequence encoding BglG PRD1 (amino acid 65-172) and BglG PRD2 (amino acid 175-278) in pST6#1, a derivative of MBPL-/gp21(338-445) (Center et al., 1998) . pLF-HPr and pLF-EI, which code for His-tagged HPr and His-tagged EI expressed from the T7 promoter, were described previously (Fux et al., 2003a) . To construct pETLL-HPr(H15A), pETLL-EI(H189A), pETLL-EI(Nter), and pETLL-EI(Cter), 260, 1730, 711, and 960 bp NdeI-BamHI fragments were amplified by PCR from pQELL-HPr(H15A) (Raveh et al., 2009 ), pQELL-EI(H189A) (Raveh et al., 2009 ) and pLF-EI (Fux et al., 2003a) , encoding HPr(H15A), EI(H189A), and wild-type EI, respectively, and cloned between the unique NdeI and BamHI in pLF-HPr or pLF-EI.
Plasmids used for the LexA-based two-hybrid system: pMS604 and pDP804, express a LexA 1-87 WT-Fos zipper fusion and a LexA 1-87 408-Jun zipper fusion, respectively, under the control of a lacUV5 promoter bearing a down mutation within the ribosomal binding site (Dmitrova et al., 1998) .
pLL1, pLL3, pLL1-G, pLL-G(D100N), pLL-G(H160Y) and pLL-G(H208R) were described before (Lopian et al., 2003) . pLF1-PRD1 and pLF1-PRD2 (Fux et al., 2003b) encode BglG-PRD1 and BglG-PRD2, respectively. To construct pLL3-HPr and pLL3-HPr(H15A), 288 bp XhoI-BamHI fragments were amplified by PCR from pLFHis-HPr (Fux et al., 2003a) and pETLLHPr(H15A), encoding HPr and HPr(H15A), respectively, and cloned between the unique XhoI and BglII in pLL3.
To construct pLL3-EI, a 1728 bp XhoI-BamHI fragment encoding EI was amplified by PCR from pLFHis-EI (Fux et al., 2003a) and cloned between the unique XhoI and BglII in pLL3. pLL3-EI(H189A) was constructed by replacing the 587 bp XmaI-KpnI fragment of pLL3-EI with the equivalent fragment from pBADLLEI(H189A), carrying the indicated mutation in EI. To construct pLL3-EI(Nter) and pLL3-EI(Cter), 711 or 960 bp XhoI-BamHI fragments, encoding the N-terminal and C-terminal domains of EI, respectively, were amplified by PCR from pLFHis-EI (Fux et al., 2003a) and cloned between the unique XhoI and BglII in pLL3. All fusion proteins constructed during this study for the two-hybrid analyses are derivatives of pDP804 and, hence, contain a 3 amino acids linker (val, thr, val) between the studied protein and the LexA derivative.
The nucleotide sequence of all constructs involving PCR-generated fragments was confirmed by DNA sequence determination. Expression and stability of the fusion proteins was confirmed by Western blot analysis. Representative analyses are shown in Fig. S2 . Functionality of EI and HPr fusion proteins was indicated by the ability of MG1655 pts cells, which contained the constructs encoding these fusion proteins together with their native counterparts (HPr and EI, respectively), to grow on mannitol and to generate red colonies on MacConkey-mannitol plates, and by the ability of 
Immunoblot analysis
Proteins were separated on 10% SDS-polyacrylamide gels. Gels were subjected to Western analysis essentially as previously described (Nussbaum-Shochat and Amster-Choder, 1999). The following specific antibodies were used: anti-mCherry polyclonal antibodies ( The number of cells containing 0, 1, 2 or 3 fluorescent foci was determined by counting four hundred (400) cells in each case. Cells were grown in LB to mid-logarithmic phase. The numbers represent percentage of cells that contain the given number of foci in the population. b 1-one polar focus; 2-two polar foci; 3-three foci at the poles and at sites of future poles; 0-no detectable fluorescent foci. The mCherry-tagged proteins were expressed from the chromosome or from a plasmid, as specified.
